Inflammatory breast cancer: What we know and what we need to learn

Oncologist

Volumn 17, Issue 7, 2012, Pages 891-899

  Yamauchi, Hideko ^a   Woodward, Wendy A ^b   Valero, Vicente ^b   Alvarez, Ricardo H ^b   Lucci, Anthony ^b   Buchholz, Thomas A ^b   Iwamoto, Takayuki ^b   Krishnamurthy, Savitri ^b   Yang, Wei ^b   Reuben, James M ^b   Hortobágyi, Gabriel N ^b   Ueno, Naoto T ^b  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inflammatory breast cancer; Systemic therapy; Targeted therapy

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; INITIATION FACTOR 4A; LAPATINIB; PACLITAXEL; RHO FACTOR; SEMAXANIB; TAXANE DERIVATIVE; TRASTUZUMAB; UVOMORULIN;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; BIOPSY; BREAST RECONSTRUCTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGITAL MAMMOGRAPHY; ECHOGRAPHY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; LYMPHANGIOGENESIS; MASTECTOMY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TISSUE DOPPLER IMAGING;

FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY;

EID: 84864129824     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0039     Document Type: Review

References (73)

1. Hance KW, Anderson WF, Devesa SS et al. Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-975.
2. Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer 1938;33:33-49.
3. Gonzalez-Angulo AM, Hennessy BT, Broglio K et al. Trends for inflammatory breast cancer: Is survival improving? The Oncologist 2007;12:904-912.
4. Haaggensen C. Inflammatory Carcinoma. Disease of the Breast. Philadelphia: W.B. Saunders, 1971:576-584.
5. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer 1974;33: 1045-1047.
6. Bonnier P, Charpin C, Lejeune C et al. Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? Int J Cancer 1995; 62:382-385.
7. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22:515-523.
8. Mourali N, Muenz LR, Tabbane F et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 1980;46:2741-2746.
9. Bonnier P, Romain S, Charpin C et al. Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer 1995;62:138-144.
10. Van Laere S, Van der Auwera I, Van den Eynden GG et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005;93:237-246.
11. Bieche I, Lerebours F, Tozlu S et al. Molecular profiling of inflammatory breast cancer: Identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-6795.
12. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004;64:8558-8565.
13. Charafe-Jauffret E, Tarpin C, Viens P et al. Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008;35:41-50.
14. Bekhouche I, Finetti P, Adelaide J et al. Highresolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS One 6:e16950.
15. Bertucci F, Finetti P, Birnbaum D et al. Gene expression profiling of inflammatory breast cancer. Cancer 2010;116:2783-2793.
16. Harvey HA, Lipton A, Lawrence BV et al. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol 1982;21:42-44.
17. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65:2170-2178.
18. Iwamoto T, Bianchini G, Qi Y et al. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 2011;125:785-795.
19. Van Laere S, Limame R, Van Marck EA et al. Is there a role for mammary stem cells in inflammatory breast carcinoma? A review of evidence from cell line, animal model, and human tissue sample experiments. Cancer 2010;116:2794-2805.
20. Xiao Y, Ye Y, Yearsley K et al. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 2008;173:561-574.
21. Anderson WF, Schairer C, Chen BE et al. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2005;22:9-23.
22. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: Mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 2002;223:829-838.
23. Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417-426.
24. Woodhams R, Matsunaga K, Iwabuchi K et al. Diffusion-weighted imaging of malignant breast tumors: The usefulness of apparent diffusion coefficient (ADC) value andADCmap for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005;29:644-649.
25. Guo Y, Cai YQ, Cai ZL et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16:172-178.
26. Carkaci S, Macapinlac HA, Cristofanilli M et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: Preliminary data. J Nucl Med 2009;50:231-238.
27. Niikura N, Liu J, Hayashi N et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: A single-institution retrospective analysis. The Oncologist 2011;16:155-164.
28. Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: Analysis of 114 cases. J Surg Oncol 1981;18:355-361.
29. Haagensen CD, Stout AP. Carcinoma of the breast. III. Results of treatment, 1935-1942. Ann Surg 1951; 134:151-172.
30. Lamb CC, Eberlein TJ, Parker LM et al. Results of radical radiotherapy for inflammatory breast cancer. Am J Surg 1991;162:236-242.
31. Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at MD Anderson Cancer Center Cancer Chemother Pharmacol 1997;40: 321-329.
32. Koh EH, Buzdar AU, Ames FC et al. Inflammatory carcinoma of the breast: Results of a combined-modality approach-MD Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990;27:94-100.
33. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg 1994;18: 87-92.
34. Buzdar AU, Singletary SE, Booser DJ et al. Combined modality treatment of stage III and inflammatory breast cancer. MD Anderson Cancer Center experience. Surg Oncol Clin N Am 1995;4:715-734.
35. Cristofanilli M, Buzdar AU, Sneige N et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775-1782.
36. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The MD Anderson Cancer Center experience. Clin Breast Cancer 2004;4:415-419.
37. Baldini E, Gardin G, Evagelista G et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 2004;5:358-363.
38. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 1989;43:201-208.
39. Guerin M, Sheng ZM, Andrieu N et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990;5:131-135.
40. Parton M, Dowsett M, Ashley S et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004;13:97-103.
41. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-1838.
42. Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 2003;4:348-353.
43. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21:46-53.
44. Baselga J, Semiglazov V, Maniknas G. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer (IBC): Data from the NOAH (neoadjuvant herceptin) phase III trial. Eur J Cancer 2007;5 (suppl): 193.
45. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (theNOAHtrial):Arandomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-384.
46. Cristofanilli M, Boussen H, Baselga J et al. Aphase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract 1]. Breast Cancer Res Treat 2006;100(suppl 1).
47. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
48. MD Anderson Cancer Center. Phase II neoadjuvant in inflammatory breast cancer. Available at http://www. clinicaltrials.gov/ct2/show/NCT00756470, accessed April 10, 2012.
49. Yamauchi H, Cristofanilli M, Nakamura S et al. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 2009;6:387-394.
50. Overmoyer B, Fu P, Hoppel C et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: Results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res 2007;13: 5862-5868.
51. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-777.
52. van Golen KL, Davies S, Wu ZF et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-2519.
53. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-514.
54. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-3652.
55. Cohen LH, Pieterman E, van Leeuwen RE et al. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 2000;60:1061-1068.
56. Sparano JA, Moulder S, Kazi A et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 2009;15:2942-2948.
57. Colpaert CG, Vermeulen PB, Benoy I et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003;88:718-725.
58. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001;61:5231-5241.
59. Kleer CG, van Golen KL, Braun T et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001;14:458-464.
60. Charafe-Jauffret E, Tarpin C, Bardou VJ et al. Immunophenotypic analysis of inflammatory breast cancers: Identification of an "inflammatory signature. " J Pathol 2004;202:265-273.
61. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype. Clin Cancer Res 2006;12: 5047-5054.
62. Silvera D, Arju R, Darvishian F et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009;11:903-908.
63. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis 2005;22:67-73.
64. Fleming RY, Asmar L, Buzdar AU et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 1997;4:452-461.
65. Curcio LD, Rupp E, Williams WL et al. Beyond palliative mastectomy in inflammatory breast cancer: A reassessment of margin status. Ann Surg Oncol 1999;6: 249-254.
66. Bristol IJ, Woodward WA, Strom EA et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2008;72:474-484.
67. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9: 235-242.
68. Newman LA, Kuerer HM, Hunt KK et al. Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol 1999;6:671-675.
69. Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg 1994;93:1191-1204.
70. Liao Z, Strom EA, Buzdar AU et al. Locoregional irradiation for inflammatory breast cancer: Effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 2000;47:1191-1200.
71. Woodward WA, Debeb BG, Xu W et al. Overcoming radiation resistance in inflammatory breast cancer. Cancer 2010;116:2840-2845.
72. Damast S, Ho AY, Montgomery L et al. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys 2010;77:1105-1112.
73. Pisansky TM, Schaid DJ, Loprinzi CL et al. Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol 1992; 15:376-387.